PolyPeptide Group

Biotech longerterm bet

PKU

Invested

Community Contributor

Published

14 Aug 24

PKU's Fair Value

CHF 33.10

21.5% undervalued

14 Aug

CHF 26.00

-18.9%

-4.1%

-18.9%

-4.1%

Edit anytime before May 14 2:40 AM. Then post Updates to your followers.

Author's Valuation

CHF 33.1

21.5% undervalued

PKU's Fair Value

Narrative

Updates0

PKU'sFair Value

CHF 33.1

21.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.13%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.46%

Calculation

€74.32m

Earnings '29

18.34x

PE Ratio '29

€1.36b

Market Cap '29

€1.36b

Market Cap '29

33.18m

No. shares '29

€41.08

Share Price '29

€41.08 Share Price '29

Discounted to 2024 @ 4.20% p.a.

€33.44

Fair Value '24

€33.44 Fair Value '24

Converted to CHF @ 1.0000 EUR/CHF Exchange Rate

CHF 33.44

Fair Value '24